CVD

Veradigm Reveals New Insights on the Prevalence of Cardiovascular Conditions in the U.S.

Retrieved on: 
Tuesday, February 20, 2024
Data Management, Health, Technology, Health Technology, Software, General Health, Cardiology, Real-World Evidence, Woman, Cardiovascular disease, EHR, CVD, MDRX, Data, Heart failure, Prevalence, Natural language processing, Hypertension, BMI, Death, Patient, Natural language, Body mass index, LVEF, Coronary artery disease, NLP, Dietary supplement

Veradigm today released its inaugural Veradigm Insights Report: Cardiovascular Conditions in 2024, which examines de-identified real world data for 53 million unique cardiovascular patients.

Key Points: 
  • Veradigm today released its inaugural Veradigm Insights Report: Cardiovascular Conditions in 2024, which examines de-identified real world data for 53 million unique cardiovascular patients.
  • Using structured and unstructured data from the comprehensive Veradigm Network EHR dataset, the report presents cardiovascular condition prevalence by state and three-digit zip code.
  • Veradigm also examines the prevalence of cardiovascular conditions such as dyslipidemia/hyperlipidemia and hypertension in relation to body mass index (BMI) categories.
  • Veradigm has a variety of additional data sources including clinically enriched Veradigm Network EHR Data across various therapeutic areas and the Veradigm Cardiovascular and Metabolic Registries.

Global Cardiology IT Workflow Solutions Research Report 2022-2024 and 2030 - Launch of New and Revamped Platforms Bodes Well for Market Growth

Retrieved on: 
Saturday, March 2, 2024
Cloud, Digital health, Business case, Delivery, Treatment, Data management, Growth, CVD, COVID-19, Role, Investment, Market, Pharmaceutical industry

DUBLIN, March 1, 2024 /PRNewswire/ -- The "Cardiology IT Workflow Solutions - Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • DUBLIN, March 1, 2024 /PRNewswire/ -- The "Cardiology IT Workflow Solutions - Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering.
  • The global market for Cardiology IT Workflow Solutions estimated at US$969 Million in the year 2022, is projected to reach a revised size of US$1.8 Billion by 2030, growing at a CAGR of 7.8% over the analysis period 2022-2030.
  • Cardiology IT workflow solutions have seen a significant rise in adoption, driven by the increasing reliance on IT for managing patient data in cardiology departments globally.
  • As the healthcare industry continues to evolve, especially in the post-COVID-19 period, the cardiology IT workflow solutions market is expected to witness continued growth and innovation.

New clinical trial shows that algae-based omega-3 lecithin AlmegaPL® provides better cardiovascular health support compared to traditional omega-3 fish oils

Retrieved on: 
Thursday, February 15, 2024
DHA, Multimedia, Absorption, VLDL, Cholesterol, Very low-density lipoprotein, Cardiovascular disease, Food, LDL, CVD, Heart, Death, Human, Triglyceride, World Health Organization, BMI, EPA, Clinical trial, Disease, IDL, Research, Dietary supplement

HOUSTON, Feb. 15, 2024 /PRNewswire/ -- Qualitas Health, LLC (dba iwi life) The results of a new clinical trial show evidence that the microalgae-derived AlmegaPL®, the foundational ingredient produced by iwi life™, delivers clinically relevant results decreasing triglycerides by 14% and remnant cholesterol such as very-low-density lipoprotein (VLDL) and intermediate-density lipoprotein (IDL) by up to 25%.1,2  "This marks the second clinical trial endorsing the use of AlmegaPL® algal lecithin to support cardiovascular health in a generally healthy population," says Dr. Eneko Ganuza, a principal investigator who led the research.

Key Points: 
  • The new clinical trial led by Dr. Ganuza and sponsored by Qualitas Health was initiated to uncover just how effective an over-the-counter supplement can be in supporting cardiovascular health in the real-world population.
  • The findings support existing beliefs that EPA-only omega-3s like AlmegaPL® could provide greater cardiovascular benefits when compared to traditional sources of omega-3s like fish and krill oil that contain both EPA and DHA.
  • This highlights the use of naturally sourced AlmegaPL® algal oil as an over-the-counter supplement to help support cardiovascular health in the general healthy population."
  • There is something about the unique polar form in which this algal lecithin yields the omega-3s that prove highly beneficial to our heart health."

Cardio Diagnostics Holdings, Inc. Expands HeartRisk™ Platform Offering to Diverse Markets in Conjunction with Nationwide Rollout

Retrieved on: 
Thursday, February 15, 2024
General Health, Professional Services, Data Management, Technology, State, Local, Artificial Intelligence, Data Analytics, Cardiology, Biotechnology, Human Resources, Health, Public Policy, Government, Prison, Intelligence, Investment, Smoking, Transport, Conditional sentence, CVD, Cardiovascular disease, Entrepreneurship, Risk, Consultant, Prevalence, Cardio, CHD, Hypertension, Death, Organization, Medicine, Workforce, Medical device

Cardio Diagnostics Holdings, Inc. (Nasdaq: CDIO), an AI-driven precision cardiovascular medicine company, announced today the nationwide rollout and a significant expansion of its groundbreaking HeartRisk™ platform.

Key Points: 
  • Cardio Diagnostics Holdings, Inc. (Nasdaq: CDIO), an AI-driven precision cardiovascular medicine company, announced today the nationwide rollout and a significant expansion of its groundbreaking HeartRisk™ platform.
  • This expansion extends the reach of its proprietary data intelligence platform to correctional facilities, risk-bearing providers engaged in value-based contracts, and broker and benefits consultants.
  • "By expanding our HeartRisk™ platform, we're not just innovating within traditional healthcare sectors but breaking new ground in diverse markets.
  • From correctional facilities to value-based care providers and workplace wellness programs to brokerage and benefits consultants, our precision cardiovascular solutions provide actionable insights.

Semiconductor Grade Ammonia Market Size to Grow USD 681.5 Million by 2030 at a CAGR of 6.2% | Valuates Reports

Retrieved on: 
Wednesday, February 14, 2024
Ammonia, USD, Investment, Miniaturization, Biophysical environment, Growth, Electronics, CVD, Safety, PPT, SIP, Semiconductor industry, Semiconductor

The Global Semiconductor Grade Ammonia Market was valued at USD 422 Million in 2023 and is anticipated to reach USD 681.5 Million by 2030, witnessing a CAGR of 6.2% during the forecast period 2024-2030.

Key Points: 
  • The Global Semiconductor Grade Ammonia Market was valued at USD 422 Million in 2023 and is anticipated to reach USD 681.5 Million by 2030, witnessing a CAGR of 6.2% during the forecast period 2024-2030.
  • Claim Your Free Sample Now: https://reports.valuates.com/request/sample/QYRE-Auto-34U16199/Global_Se...
    The ongoing rise of the semiconductor sector, which requires ultra-pure chemicals for production processes, is the main factor driving the market for semiconductor grade ammonia.
  • Because of its strict quality standards, semiconductor grade ammonia is essential to maintaining the dependability and functionality of electronic components.
  • The need for semiconductor grade ammonia is rising due to the semiconductor industry's constant innovation and growth.

Semiconductor Grade Ammonia Market Size to Grow USD 681.5 Million by 2030 at a CAGR of 6.2% | Valuates Reports

Retrieved on: 
Wednesday, February 14, 2024
Ammonia, USD, Investment, Miniaturization, Biophysical environment, Growth, Electronics, CVD, Safety, PPT, SIP, Semiconductor industry, Semiconductor

The Global Semiconductor Grade Ammonia Market was valued at USD 422 Million in 2023 and is anticipated to reach USD 681.5 Million by 2030, witnessing a CAGR of 6.2% during the forecast period 2024-2030.

Key Points: 
  • The Global Semiconductor Grade Ammonia Market was valued at USD 422 Million in 2023 and is anticipated to reach USD 681.5 Million by 2030, witnessing a CAGR of 6.2% during the forecast period 2024-2030.
  • Claim Your Free Sample Now: https://reports.valuates.com/request/sample/QYRE-Auto-34U16199/Global_Se...
    The ongoing rise of the semiconductor sector, which requires ultra-pure chemicals for production processes, is the main factor driving the market for semiconductor grade ammonia.
  • Because of its strict quality standards, semiconductor grade ammonia is essential to maintaining the dependability and functionality of electronic components.
  • The need for semiconductor grade ammonia is rising due to the semiconductor industry's constant innovation and growth.

Buchanan Obtains Preliminary Win with International Trade Commission's Affirmative Determination in Trade Cases on Wine Bottles from Chile, China, and Mexico

Retrieved on: 
Monday, February 12, 2024
Wine, Multimedia, International trade, Commerce, CVD, Glass, Commission

The Commission's unanimous affirmative vote comes in response to petitions filed December 29, 2023, by the U.S. Glass Producers Coalition.

Key Points: 
  • The Commission's unanimous affirmative vote comes in response to petitions filed December 29, 2023, by the U.S. Glass Producers Coalition.
  • The petitions allege that unfairly dumped and subsidized wine bottles are injuring the domestic industry.
  • The Commission's affirmative preliminary injury determination paves the way for the Department of Commerce to move forward with its investigations.
  • Commerce is expected to issue its preliminary CVD determination in March 2024 and its preliminary AD determinations in June 2024.

Nudj Health Expands Virtual Cardiac Rehab Services to Patients with Ornish Lifestyle Medicine by Sharecare

Retrieved on: 
Tuesday, February 6, 2024
Partnership, ACLM, CVD, Human, Heart, Cardiovascular disease, News, Exercise, Sleep, SCR, Zoom, Patient, Splenic infarction, Conditional sentence, Diagnosis, ICR, Lifestyle medicine, Love, Depression, Cardiac rehabilitation, Mental health, Physician, Quality of life, Heart failure, Social support, Death, Health, Moyamoya disease, Apolipoprotein, American Heart Association, Medicare, Nursing

Nudj Cardiac Complete, in partnership with Ornish Lifestyle Medicine by Sharecare, allows physician groups to provide cardiac rehab to patients at home thus increasing access, adoption and adherence to cardiac rehabilitation.

Key Points: 
  • Nudj Cardiac Complete, in partnership with Ornish Lifestyle Medicine by Sharecare, allows physician groups to provide cardiac rehab to patients at home thus increasing access, adoption and adherence to cardiac rehabilitation.
  • Nudj is increasing access, adoption and adherence to these vital cardiac rehab services and enabling physicians to meet their patients no matter where they are on their health journey.
  • Nudj Cardiac Complete includes three major care pathway service offerings:
    Cardiac Wellness/Risk Reduction: Using the evidence-based model of Collaborative Care, the Nudj Health American College of Lifestyle Medicine (ACLM) certified program delivers lifestyle and behavioral health modifications every month to patients.
  • I’m pleased that Nudj Health will now offer my intensive cardiac rehabilitation program virtually,” said Dean Ornish, M.D., founder of Ornish Lifestyle Medicine.

Toku Obtains CE and UKCA Marks for AI Cardiovascular Risk Assessments Through the Eye

Retrieved on: 
Monday, February 5, 2024
Cardiology, Biotechnology, Optical, General Health, Health, Artificial Intelligence, Medical Devices, Technology, Multimedia, Intelligence, CVD, University College London, History, Cardiovascular disease, Patient, Safety, Splenic infarction, Kidney, Stroke, Temperature, Retina, Pharmacy, Gold, Heart rate, Quality of life, UKCA, Risk, CE, Eye, Blood pressure, Medical device

Toku, Inc., a commercial medical device company specializing in AI assessment of retinal images, announced today that it has obtained CE and UKCA Marks for its patented CLAiR technology.

Key Points: 
  • Toku, Inc., a commercial medical device company specializing in AI assessment of retinal images, announced today that it has obtained CE and UKCA Marks for its patented CLAiR technology.
  • The CLAiR technology integrates readily with existing retinal cameras, to provide real-time CVD risk assessments with accuracy comparable to gold standard cardiovascular risk assessments (which typically require blood tests and can take weeks).
  • The AI-powered CLAiR technology identifies elevated cardiovascular risk by analyzing minute changes in the retina and its vasculature.
  • CLAiR will enable healthcare providers in various settings to identify elevated cardiovascular risk in adult patients with no known history of cardiovascular disease.

CDC Foundation's Live to the Beat campaign spotlights cardiovascular disease in Black women, issuing a call-to-action to help Black women prioritize self-care for their own heart health

Retrieved on: 
Thursday, February 1, 2024
Steps, Anxiety, CVD, JAMA, Research, Health equity, Cardiovascular disease, News, House, American Medical Association, Moyamoya disease, Friends, Beat, American Heart Month, CDC, Depression, Social media, Health education, Challenge, Risk, Journal, Cancer, EST, Stroke, Health, White, Woman

Black women are bearing the brunt of the toll cardiovascular disease (CVD) is having on women in the United States.

Key Points: 
  • Black women are bearing the brunt of the toll cardiovascular disease (CVD) is having on women in the United States.
  • CDC Foundation's Live to the Beat campaign is launching a "Heart2Heart Challenge" to encourage Black women to give themselves permission to prioritize self-care for their own heart health.
  • "Black women are the figurative heartbeats of Black families and communities, but many of their own hearts are in trouble.
  • Now entering its third year, the CDC Foundation's Live to the Beat campaign is CDC's first national cardiovascular disease prevention campaign developed for the Black community.